To date, all CVOTs for dipeptidyl peptidase 4 (DPP-4) inhibitors, 4-7 glucagon-like peptide-1 receptor agonists (GLP-1 RAs), 8-13 and sodium-glucose transport protein 2 (SGLT-2) inhibitors 14-16 have documented a lack of increased CV risk (non-inferiority) with the investigational product in patients with T2DM compared to placebo
Blood tests allow providers to measure growth hormone activity and ensure treatment is working effectively without pushing hormone levels too high
Insurance coverage for Zepbound depends on your plan, deductible, and copay amounts, and may require prior authorization
If you are ever in doubt, contact your healthcare provider or pharmacist
Long-term studies such as SURMOUNT-4 demonstrate that continued tirzepatide treatment helps maintain weight loss, while discontinuation typically leads to weight regain, suggesting ongoing pharmacological activity
Evidence and regulatory status reviewed August 1, 2026: In July 2026, an FDA advisory committee considered Epitalon free base and Epitalon acetate for possible inclusion on the section 503A Bulks List in relation to insomnia